Clinical effect of aerosol inhalation of recombinant human α2b injection on treating pediatric viral pneumonia
- VernacularTitle:重组人α2b注射液雾化吸入治疗小儿病毒性肺炎的临床效果观察
- Author:
Feng LI
1
Author Information
1. 江西省景德镇市妇幼保健院儿科
- Keywords:
Recombinant human α2b injection;
Aerosol inhalation;
Treatment;
Pediatric viral pneumonia
- From:
China Modern Doctor
2018;56(15):61-63
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of aerosol inhalation of recombinant human α2b injection for children with viral pneumonia. Methods 50 children with viral pneumonia admitted to our hospital from November 2016 to November 2017 in our hospital were selected and divided into control group and observation group according to different inhalation drugs. The control group was given ribavirin aerosol inhalation therapy and the observation group was treated with nebulization of recombinant human α2b injection. The clinical efficacy and changes of serological inflammatory indicators were compared between the two groups. Results The good rate of observation group was 96. 00％ (24/25) and was significantly higher than that of control group which was 80. 00％ (20/25)(P＜0. 05). Blood routine examination, erythrocyte sedimentation rate, C-reactive protein, IL-6 (interleukin-6) and IL-10 (interleukin-10) of serum inflammatory indexes in observation group were all significantly lower than those in the control group (P＜0. 05). Conclusion The inhalation of recombinant α2b injection for the treatment of viral pneumonia in children has a definite clinical effect. It has a high good rate of clinical treatment and has a definite curative effect on the reduction of serological inflammatory indicators which is worth promoting.
